Last Price$2.61Cboe Real-Time Last Sale as of 10:59AM ET 1/31/23
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Today's Change+0.06(2.16%)
Bid (Size)$2.60 (1,692)
Ask (Size)$2.61 (1,300)
Day Low / High$2.57 - 2.65
Volume440.3 K

Agenus Shares Expanded Data From Phase 1 Trial of Botensilimab in Different Cancer Types; Stock Rises

1:29PM ET 11/14/2022 MT Newswires
Agenus (AGEN) said Monday that expanded data from a phase 1 trial showed the potential of botensilimab and balstilimab to treat a range of immunotherapy-resistant tumors.

The trial included expansion groups for microsatellite stable-colorectal cancer, or MSS CRC, recurrent platinum refractory/resistant ovarian, sarcoma, and PD-(L)1 relapsed/refractory non-small cell lung cancer, or NSCLC, the company said.

Data show that overall response rates ranged from 22% in MSS-CRC to 60% in PD-(L)1 refractory NSCLC and that botensilimab was well tolerated during the study, the company said.

Agenus also said that it has started phase 2 trials of botensilimab in advanced MSS-CRC and advanced melanoma.

The company's shares rose nearly 18% in recent trading activity.

Price: 2.96, Change: +0.44, Percent Change: +17.73